Clinical Trials Browser

Phase 1/2 × Myelodysplastic Syndromes × CB-839 × Clear all

NCT03047993 2024-05-14

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Phase 1/2 Completed

28 enrolled 8 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic